2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2767 Comparison of functional and comorbidity-based assessment models in older adults with diffuse large B-cell lymphoma

Hemavathi Baskarane, MD DM, Esther Drill, DrPH2, Suheil Albert Atallah-Yunes, MD3, Alexander P. Boardman, MD4, Kevin David, MD5, Zachary Epstein-Peterson, MD6, Lorenzo Falchi, MD7, Paola Ghione, MD, MS8, Steven Horwitz, M.D.9, Andrew Intlekofer, MD, DPhil10, Anita Kumar, MD11, Jennifer Kimberly Lue, M.D.12, Efrat Luttwak, Luttwak, MD13, Alison Moskowitz, MD14, Ariela Noy, MD15, Colette Owens, MD16, Maria Lia Palomba, MD17, Mark Roschewski, MD18, Gilles Salles I, MD, PhD19, Quinlan Sievers, MD, PhD20, Raphael Steiner, MD21, Robert Stuver, MD22, Santosha Vardhana, MD, PhD23, Jasmine Zain, M.D.24, Andrew Zelenetz, MD25, Paul Hamlin, MD26, Pallawi Torka, MD27
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, United States, Memorial Sloan Kettering Cancer Center, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, United States

Background

Treatment selection for older adults with diffuse large B-cell lymphoma (DLBCL) is primarily guided by performance status (PS) and disease-related factors such as the age-adjusted International Prognostic Index (aa-IPI), which incompletely capture patient vulnerability. Several geriatric and comorbidity-based tools, including the Vulnerable Elders Survey-13 (VES-13), Charlson Comorbidity Index (CCI), Cancer and Aging Research Group (CARG) toxicity score, Timed Up and Go (TUG), simplified geriatric assessment (sGA), and Non-Hodgkin Lymphoma-5 (NHL-5), have demonstrated prognostic value in older adults with lymphoma, but their comparative performance remains uncertain. We evaluated the prognostic utility and concordance of established geriatric and comorbidity assessment models in a homogeneously treated cohort of older adults with DLBCL.

Methods:

We previously conducted a prospective geriatric assessment study in older adults with NHL demonstrating that impairments in various geriatric domains were independently associated with treatment-related toxicity and survival (Torka et al, ASH 2023). In this analysis, patients ≥60 years with newly diagnosed DLBCL treated with chemotherapy were included. Baseline geriatric assessment and CARG risk scores were calculated prospectively. VES-13, CCI, and NHL-5 were derived retrospectively from available data; sGA could not be reconstructed retrospectively. VES-13 was categorized as 0-2 (robust) and ≥3 (vulnerable/frail), CCI was categorized as 1–2 (low), 3–4 (moderate), and ≥5 (high); and NHL-5 was categorized as low (score 0) and intermediate/high (score ≥1). Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using Cox regression. Concordance between instruments was assessed using Kendall’s tau coefficient. Because of the limited number of events, bivariable models were used for adjusted analyses.

Results:

Among 113 patients, median age was 73 years (IQR, 66–78), 44% were women, 67% had stage III/IV disease, and 51% had high-intermediate/high aa-IPI. Frontline therapy included R-CHOP (81%), R-EPOCH (19%), and polatuzumab-R-CHP (1%). High CARG risk (≥10) was present in 51%; VES-13 ≥3 in 35%; CCI low/moderate/high in 23%/65%/12%; and NHL-5 ≥1 in 34%.

VES-13 ≥3 was associated with inferior PFS (HR, 3.21; 95% CI, 1.57–6.57; p=0.001) and OS (HR, 5.01; 95% CI, 2.06–12.2; p<0.001). Increasing CCI category was associated with inferior PFS (p=0.002) and OS (p<0.001); compared with CCI 1–2, CCI ≥5 was associated with inferior PFS (HR, 7.32; 95% CI, 2.24–23.9) and OS (HR, 13.2; 95% CI, 2.83–61.4). NHL-5 ≥1 was associated with inferior PFS (HR, 2.17; 95% CI, 1.07–4.41; p=0.034) and OS (HR, 2.74; 95% CI, 1.18–6.35; p=0.020).

Concordance between models was modest. CCI correlated moderately with NHL-5 (τ=0.49; p<0.001), consistent with NHL-5 being a derivative of CCI. VES-13 showed modest correlation with CCI (τ=0.38; p<0.001) and CARG (τ=0.30; p=0.002), but limited correlation with NHL-5 (τ=0.17; p=0.08). CARG and NHL-5 were not correlated (τ=−0.02; p=0.84).

After adjustment for age, stage, and aa-IPI, VES-13, CCI, and NHL-5 each remained independently associated with PFS and OS. In pairwise models, CCI remained independently associated with both PFS and OS after adjustment for NHL-5, whereas NHL-5 lost significance after adjustment for CCI, consistent with NHL-5 being derived from CCI. VES-13 remained associated with both endpoints after adjustment for NHL-5, while its association was attenuated after adjustment for CCI. Further analyses incorporating additional clinical and treatment variables are ongoing.

Conclusion:

Patient vulnerability in older adults with DLBCL is multidimensional and is not adequately captured by a single assessment tool. Functional impairment (VES-13) and comorbidity burden (CCI) provide complementary prognostic information beyond standard clinical risk factors, whereas NHL-5 did not improve prognostic discrimination beyond CCI. Integrating functional and comorbidity assessment into prognostic models may better define fitness, improve risk stratification, and inform individualized frontline treatment strategies for older adults with DLBCL.

Hemavathi Baskarane, MD DM: No relevant conflicts of interest to declare.